Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1477-44-7

Post Buying Request

1477-44-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1477-44-7 Usage

General Description

18-BETA-GLYCYRRHETINIC ACID METHYL ESTER is a chemical compound that belongs to the family of glycyrrhetinic acid derivatives. It is derived from licorice root and has been found to possess various pharmacological properties, including anti-inflammatory, antimicrobial, and anti-tumor activities. 18-BETA-GLYCYRRHETINIC ACID METHYL ESTER has been studied for its potential therapeutic applications in skin disorders, liver diseases, and cancer treatment. Additionally, it has shown promise in the treatment of metabolic syndrome and diabetes. 18-BETA-GLYCYRRHETINIC ACID METHYL ESTER demonstrates potential as a natural, bioactive compound with diverse medicinal properties and may hold promise for the development of new pharmaceuticals and nutraceuticals.

Check Digit Verification of cas no

The CAS Registry Mumber 1477-44-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,4,7 and 7 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1477-44:
(6*1)+(5*4)+(4*7)+(3*7)+(2*4)+(1*4)=87
87 % 10 = 7
So 1477-44-7 is a valid CAS Registry Number.
InChI:InChI=1/C31H48O4/c1-26(2)22-9-12-31(7)24(29(22,5)11-10-23(26)33)21(32)17-19-20-18-28(4,25(34)35-8)14-13-27(20,3)15-16-30(19,31)6/h17,20,22-24,33H,9-16,18H2,1-8H3/t20-,22-,23-,24+,27+,28-,29-,30+,31+/m0/s1

1477-44-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 18-β-GLYCYRRHETINIC ACID METHYL ESTER

1.2 Other means of identification

Product number -
Other names glycyrrhetinic acid methyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1477-44-7 SDS

1477-44-7Relevant articles and documents

Structure-based design of glycyrrhetinic acid derivatives as potent anti-sepsis agents targeting high-mobility group box-1

Wang, Yuanyuan,Yu, Zongmin,Yuan, Hu,Chen, Hao,Xie, Ning,Wang, Zhibin,Sun, Qingyan,Zhang, Weidong

, (2020/11/27)

Novel Glycyrrhetinic Acid (GA) derivatives with fused heterocycles on A ring were structure-based designed and synthesized. Their potential anti-inflammatory effects were investigated by a classical LPS stimulated macrophage model. Surface plasmon resonance (SPR) was used to verify the binding of GA analogues with HMGB1. A preliminary structure–activity relationship was summarized and an analogue GA-60 with ortho-methoxybenzyl pyrozole showed stronger anti-inflammatory effect and higher affinity for HMGB1 with a Kd value of 12.5 μM. In addition, this compound exhibited excellent inhibitory functions on NO (96%), TNF-α (94%), and IL-6 (100%), by interfering with phosphorylation of p38, ERK, JNK MAPKs, as well as that of NF-κB p65 and IKKα/β. Moreover, GA-60 extended the survival of either the classic CLP-induced or LPS-induced sepsis mouse models. Molecular modeling predictions further supported these findings, clearly indicating that inhibiting HMGB1 release, using fused heterocyclic GA derivatives, is a promising strategy for treatment of sepsis.

Preparation method of 18 beta-methyl glycyrrhetinate

-

Paragraph 0024; 0030-0063, (2021/11/27)

The invention provides a preparation method of 18 beta-methyl glycyrrhetinate, which comprises the following steps: taking 18 beta-glycyrrhetinic acid and trimethylsilyl diazomethane as raw materials, and reacting to prepare the 18 beta-methyl glycyrrhetinate. According to the invention, 18 beta-glycyrrhetinic acid is used as a starting material and is subjected to one-step methyl esterification reaction with trimethylsilyl diazomethane to obtain 18 beta-methyl glycyrrhetinate, the synthesis process is simple, the synthesis process conditions are mild, the yield is up to 99.2% or above, the product quality is good, and the content is greater than 99.5%. Besides, through selection of a plurality of parameters such as the solvent, the reaction time and the material dosage, the yield and the purity of the reaction are further improved, and a basis is provided for industrial production.

Synthesis and anti-hepaticfibrosis of glycyrrhetinic acid derivatives with inhibiting COX-2

Bai, Zhongjie,He, Dian,Mohammed, Eyad Abdulwhab Hamoud,Wang, Yanni,Wang, Zhen,Zhang, Qiuping,Zhao, Quanyi

, (2020/04/08)

Many tests have shown cyclooxygenase-2 (COX-2) was closely related to the activation of hepatic stellate cells (HSCs), which further promoting the onset and development of hepatic fibrosis. According to these research findings, a series of glycyrrhetinic acid derivatives were designed and synthesized. Meanwhile, their anti-hepaticfibrotic activities were evaluated in vitro and in vivo. Firstly, in the tests of the cell models, all the compounds displayed anti-proliferative effect on the HSC-T6 activated by (transforming growth factor beta) TGF-β1 (10 ng/mL). Among them, compounds 2 and 16 exhibited a stronger activity than the others, and their IC50 values were 17.6 μM and 30.3 μM, respectively; both of them were low toxicity to normal HSC-T6 cells and WI38 cells, and they inhibited the activated HSC-T6 cells proliferation by promoting apoptosis and resting them at the G0/G1 phase. Secondly, compounds 2 and 16 displayed strong inhibitory effect on activation of HSCs; they not only inhibited the expression of α-SMA and Col1 in the activated HSC-T6 cells, but also decreased the levels of COX-2, TGF-β1 and (reactive oxygen species) ROS in a concentration-dependent manner; they down-regulated the levels of three biomarkers in the process of test, but this decrease did not change linearly with the action time of compound. Thirdly, for the rats which induced with (carbon tetrachloride) CCl4, the symptoms of liver fibrosis in rats were significantly alleviated after successive administration the tested compound for 14d; the α-SMA level in liver tissue decreased in a concentration dependent manner; and the liver cell necrosis and the fat collagen fiber decreased significantly compared with the positive control group; furthermore, inflammatory infiltration was significantly lower than that of the control. This suggests the compounds possibly are candidates for hepatic fibrosis with promising application in clinic.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1477-44-7